NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) stock jumped 6.00% on Friday to $16.61 against a previous-day closing price of $15.67. With 1.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.45 whereas the lowest price it dropped to was $15.11. The 52-week range on NRBO shows that it touched its highest point at $123.42 and its lowest point at $7.39 during that stretch. Beta for the stock currently stands at 0.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NRBO was down-trending over the past week, with a drop of -33.08%, but this was up by 43.55% over a month. Three-month performance surged to 20.89% while six-month performance fell -39.33%. The stock lost -86.36% in the past year, while it has lost -54.62% so far this year.
Float and Shares Shorts:
At present, 0.89 million NRBO shares are outstanding with a float of 0.36 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.22 million, which was 0.84% higher than short shares on Jun 14, 2022. In addition to Dr. Ben Gil Price M.D. as the firm’s CEO & Pres, Dr. Matthew Bardin BCPS, Pharm.D. serves as its Sr. VP of Operations.
Through their ownership of 32.40% of NRBO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold — of NRBO, in contrast to — held by mutual funds. Shares owned by individuals account for –.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NRBO since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NRBO analysts setting a high price target of $480.00 and a low target of $480.00, the average target price over the next 12 months is $480.00. Based on these targets, NRBO could surge 2789.83% to reach the target high and rise by 2789.83% to reach the target low. Reaching the average price target will result in a growth of 2789.83% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. NRBO will report FY 2021 earnings on 04/03/2023. Analysts have provided yearly estimates in a range of -$20.10 being high and -$20.10 being low. For NRBO, this leads to a yearly average estimate of -$20.10. Based on analyst estimates, the high estimate for the next quarter is -$4.50 and the low estimate is -$4.50. The average estimate for the next quarter is thus -$4.50.